Iblias (octocog alfa)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- octocog alfa
- Company
- Bayer AG
- Status
- Withdrawn
- Therapeutic area
- Hemophilia A
- EU approval
- Thu 18 Feb 2016
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004147
- ATC
- B02BD02
- Official record
- www.ema.europa.eu
Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Iblias can be used for all age groups.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Jivi Authorised · Bayer AG
- 🇪🇺 Afstyla Authorised · CSL Behring GmbH
- 🇪🇺 Altuvoct Authorised · Swedish Orphan Biovitrum AB (publ)
- 🇪🇺 Adynovi Authorised · Baxalta Innovations GmbH
- 🇪🇺 Elocta Authorised · Swedish Orphan Biovitrum AB (publ)
- 🇪🇺 Nuwiq Authorised · Octapharma AB
- 🇪🇺 Advate Authorised · Takeda Manufacturing Austria AG
- 🇪🇺 Kovaltry Authorised · Bayer AG
- 🇪🇺 Obizur Authorised · Baxalta Innovations GmbH
- 🇪🇺 ReFacto AF Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Esperoct Authorised · Novo Nordisk A/S
- 🇪🇺 Vihuma Authorised · Octapharma AB
Follow Iblias
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.